CD123 overexpression in AML blasts and LSCs is associated with higher blast counts at diagnosis, poorer CR, and survival (127, 128), thereby establishing CD123 as a promising therapeutic target in AML. The gene discussed is IL3RA; the disease is acute myeloid leukemia.